#	Pagina
attuale pagina	/open-h2020/projects/217495/index.html

Opendata, web and dolomites

MEsHH SIGNED

DNA MEthylation for HPV-related disease among women living with HIV

Total Cost €

EC-Contrib. €

Partnership

Views

MEsHH project word cloud

Explore the words cloud of the MEsHH project. It provides you a very rough idea of what is the project "MEsHH" about.

sa 623 living overtreatment strategies lugol burkina collected pyrosequencing primary 16 positive vili 615 18 mir women 33 months detection 31 visual faso self capacity regression persistence matching carcinogenesis hpv assays 1238 progression cervical follow enrolled virus cytology thereby alone incident lesion shown inspection validation colposcopy ing n reported poor previously screening sensitivity lesions hpv16 prospective epb41l3 bf performance hiv genes data multiplex histological grade cancer swabs meshh dna prevalent relevance background africa markers acetic intraepithelial human distinguish mal neoplasia methylation wlhiv lacking combination tests clinician performed predicting referral south acid cin2 predictive stand cin coverage cadm1 endocervical iodine specificity negative via

Project "MEsHH" data sheet

The following table provides information about the project.

Coordinator	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 website: www.idibell.cat contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	158˙121 €
EC max contribution	158˙121 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2017
Funding Scheme	MSCA-IF-EF-ST
Starting year	2018
Duration (year-month-day)	from 2018-09-05 to 2020-09-04

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 website: www.idibell.cat contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (L'HOSPITALET DE LLOBREGAT)	coordinator	158˙121.00

Map

Project objective

Background: The current screening methods for cervical cancer screening among women living with HIV (WLHIV) have previously shown high sensitivity but poor specificity for the detection of high-grade cervical intraepithelial neoplasia (CIN2), resulting in over-referral for colposcopy and overtreatment of cervical lesions that may have low potential for progression to cancer. Methylation changes of human genes or HPV DNA have been reported early in carcinogenesis but their validation for predicting CIN among WLHIV is lacking. Objectives: Among 1238 WLHIV enrolled in Burkina Faso (BF; n=615) and South Africa (SA; n=623), the MesHH study aims to evaluate the performance of the DNA methylation of human genes (CADM1, MAL, MiR and EPB41L3) and HPV (HPV16/18/31/33) for the detection of prevalent and incident CIN2 compared to, or in combination with, other screening methods (visual inspection using acetic acid [VIA] or Lugol’s iodine [VILI], cytology and HPV DNA) and to evaluate the capacity of the DNA methylation markers to distinguish cervical lesion progression, persistence or regression at 16 months follow-up. Methods: The study will use endocervical swabs with matching histological data collected as part of a prospective study evaluating cervical cancer screening strategies among WLHIV in BF and SA. The DNA methylation assays for human genes (CADM1, MAL, MiR, EPB41L3) and HPV (HPV16/18/31/33) will be performed using pyrosequencing assays. Sensitivity, specificity, positive and negative predictive values for the detection of CIN2 will be estimated for the various DNA methylation markers, as stand-alone or multiplex tests. Relevance: Multiplex DNA methylation assays including a combination of human genes and HPV virus may have potential as primary screening for CIN2 among WLHIV. DNA methylation assays also have the potential to be performed using the same clinician- or self-collected sample used for cytology or HPV testing, thereby increasing screening coverage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MESHH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MESHH" are provided by the European Opendata Portal: CORDIS opendata.